Abstracts tagged "Stem cells"

Abstract Number: 902 • 2018 ACR/ARHP Annual Meeting
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Lynette Keyes-Elstein¹, Ellen Goldmuntz², Ashley Pinckney³, Leslie Crofford⁴, Daniel E. Furst⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Beverly Welch⁸ and Keith Sullivan⁹, ¹Biostatistics, Rho Federal Systems, Inc, Chapel Hill, NC, ²NIAID, NIH, Bethesda, MD, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁵UCLA, Los Angeles, CA, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) study established the long-term superiority of hematopoietic stem cell transplant (HSCT) over cyclophosphamide (CYC) [Sullivan KM, et al.…
Abstract Number: 2887 • 2017 ACR/ARHP Annual Meeting
Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation
Hiroyuki Nakamura¹, Shinsuke Yasuda¹, Atsushi Noguchi², Toshio Odani³, Yuichiro Fujieda¹, Masaru Kato¹, Kenji Oku¹, Junichi Sugita⁴, Toshiyuki Bohgaki¹, Tomoyuki Endo⁴, Takanori Teshima⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Third Department of Internal Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan, ⁴Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Systemic sclerosis (SSc) comprises diverse clinical phenotypes with variable disease courses. Some SSc patients take miserable and fatal clinical course due to rapid progressive…
Abstract Number: 851 • 2016 ACR/ARHP Annual Meeting
Perioral Autologous FAT Transplantation Is More Effective THAN Hyaluronic Acid Filler on Scleroderma Skin Fibrosis: Results from a LONG TERM Controlled Study
Nicoletta Del Papa¹, Eleonora Zaccara¹, Romina Andracco¹, Wanda Maglione¹, Francesca Pignataro¹, Fabio Caviggioli², Gabriele Di Luca³, Antonina Prafioriti⁴ and Claudio Vitali⁵, ¹Dept. Rheumatology, G. Pini Hospital, Milano, Italy, ²UOC Chirurgia Plastica, UOC Chirurgia Plastica, Multimedica Holding SpA, Milano, Italy, ³UOS Chirurgia Vascolare,, Osp. G. Pini, Milano, Italy, ⁴Pathology Unit, Istituto G.Pini, Milan, Italy, ⁵Rheumatology Section, Istituto San Giuseppe, Como, Italy
Background/Purpose: Autologous fat tissue grafting (AFTG) has been successfully used in the treatment of different sclerotic conditions, including scleroderma. We evaluated in patients with SSc…
Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 1675 • 2014 ACR/ARHP Annual Meeting
Regional Implantation of Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients with Systemic Sclerosis
Nicoletta Del Papa¹, Gabriele Di Luca², Domenico Sambataro^1,3, Eleonora Zaccara⁴, Wanda Maglione⁴, Armando Gabrielli⁵, Paolo Fraticelli⁶, Gianluca Moroncini⁵, Lorenzo Beretta^7,8, Alessandro Santaniello⁹ and Claudio Vitali¹⁰, ¹Rheumatology Unit, Istituto G.Pini, Milan, Italy, ²UOS Chirurgia Vascolare,, Osp. G. Pini, Milano, Italy, ³UOC Day Hospital Reumatologia,, G. Pini Hospital, Milano, Italy, ⁴U.O.C. Day Hospital Reumatologia, Osp. G. Pini, Milano, Italy, ⁵Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ⁶Dipartimento di Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ⁷Via Francesco Sforza 28, Ospedale Maggiore Policlinico, Milano, Italy, ⁸Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁰Sezione Reumatologia, Istituto San Giuseppe, Lecco, Italy
Background/Purpose Fingertip digital ulcers (DUs) are a rather frequent and invalidating complication in the course of systemic sclerosis (SSc), often showing a very slow or…
Abstract Number: L2 • 2012 ACR/ARHP Annual Meeting
High Dose Immunoablation and Autologous Hematopoietic Stem Cell Transplantation Versus Monthly Intravenous Pulse Therapy Cyclophosphamide in Severe Systemic Sclerosis
Jacob M. van Laar¹, Dominique Farge², Jaap K. Sont³, Kamran Naraghi⁴, Zora Marjanovic⁵, Annemie Schuerwegh⁶, Madelon C. Vonk⁷, Marco Matucci-Cerinic⁸, A.E. Voskuyl⁹, Alois Gratwohl¹⁰, Alan G. Tyndall¹¹ and EBMT/EULAR Scleroderma Study Group¹², ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Internal Medicine, Hopital St Louis, Paris, France, ³Medical Decision Making, Leiden University Medical Centre, Leiden, Netherlands, ⁴Rheumatology, The James Cook University, Middlesbrough, United Kingdom, ⁵Hematology, Hopital St Antoine, Paris, France, ⁶Leids Univ Medisch Centrum, Leiden, Netherlands, ⁷Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, ⁹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁰Hematology, University Hospital Basel, Basel, Switzerland, ¹¹Rheumatology, University of Basel, Basel, Switzerland, ¹²Rheumatology, The James Cook University Hospital, Middlesbrough, United Kingdom
Background/Purpose: High dose immunosuppressive therapy and hematopoietic stem cell transplantation (HSCT) have shown efficacy in severe systemic sclerosis (SSc) in phase I and II trials.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].